Clinical Trial Results: Positive outcomes from BrainStorm Cell Therapeutics' NurOwn trials, especially Phase 3, can significantly increase stock price. Negative or inconclusive results typically lead to a price decrease. Regulatory Decisions: FDA decisions regarding NurOwn's approval are critical. Approval would likely trigger a substantial price increase, while rejection would likely cause a significant decline. Financial Performance: The company's cash reserves, burn rate, and ability to secure funding influence investor confidence. Strong financials can stabilize or increase the price, while financial instability may lower it. Market Sentiment: General market conditions and investor sentiment towards biotech stocks can impact BCLI.US. Positive market trends may lift the stock, while negative trends could drag it down. Competition: Advances or setbacks by competitors in the ALS treatment space affect investor perceptions of NurOwn's potential market share. Successful competing therapies may lower BCLI's price. Partnerships and Collaborations: Strategic partnerships with larger pharmaceutical companies or research institutions can boost investor confidence and drive the stock price higher. Management Changes: Significant changes in the company's leadership team can impact investor sentiment. A strong, experienced management team is generally viewed positively. News and Media Coverage: Positive or negative news articles, research reports, and social media discussions can influence investor behavior and impact the stock price.